J. Notario

1.2k total citations
50 papers, 721 citations indexed

About

J. Notario is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, J. Notario has authored 50 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 18 papers in Dermatology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in J. Notario's work include Psoriasis: Treatment and Pathogenesis (21 papers), Dermatology and Skin Diseases (15 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). J. Notario is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (21 papers), Dermatology and Skin Diseases (15 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). J. Notario collaborates with scholars based in Spain, United States and Denmark. J. Notario's co-authors include J.M. Carrascosa, L. Puig, D. Vidal, P. de la Cueva, Mar Llamas‐Velasco, Antonio Martorell, D. Moreno‐Ramírez, M. Ribera, Cristina Alonso and Luísa Coderch and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

J. Notario

48 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Notario Spain 16 430 354 107 104 92 50 721
Annunziata Dattola Italy 17 371 0.9× 485 1.4× 112 1.0× 90 0.9× 108 1.2× 75 920
Arnd Jacobi Germany 17 504 1.2× 603 1.7× 147 1.4× 110 1.1× 47 0.5× 28 1.0k
Shivani B. Kaushik United States 9 490 1.1× 407 1.1× 87 0.8× 98 0.9× 111 1.2× 10 786
Nicoletta Bernardini Italy 15 372 0.9× 444 1.3× 82 0.8× 104 1.0× 230 2.5× 83 1.0k
Dagmar Wilsmann‐Theis Germany 19 739 1.7× 677 1.9× 155 1.4× 169 1.6× 95 1.0× 68 1.1k
M. Sánchez‐Regaña Spain 17 471 1.1× 401 1.1× 82 0.8× 159 1.5× 35 0.4× 43 684
Darío Kivelevitch United States 13 490 1.1× 254 0.7× 110 1.0× 112 1.1× 56 0.6× 22 643
Gamze Pişkin Netherlands 12 979 2.3× 629 1.8× 119 1.1× 114 1.1× 118 1.3× 17 1.2k
A.L.A. Kuijpers Netherlands 16 482 1.1× 241 0.7× 119 1.1× 124 1.2× 76 0.8× 23 710
E. Archier France 10 398 0.9× 406 1.1× 43 0.4× 69 0.7× 87 0.9× 15 739

Countries citing papers authored by J. Notario

Since Specialization
Citations

This map shows the geographic impact of J. Notario's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Notario with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Notario more than expected).

Fields of papers citing papers by J. Notario

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Notario. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Notario. The network helps show where J. Notario may publish in the future.

Co-authorship network of co-authors of J. Notario

This figure shows the co-authorship network connecting the top 25 collaborators of J. Notario. A scholar is included among the top collaborators of J. Notario based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Notario. J. Notario is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Daudén, E., José María Ortiz Salvador, J. Notario, et al.. (2025). Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review. Journal of Clinical Medicine. 14(2). 478–478. 2 indexed citations
2.
Pérez‐Recio, Sandra, Jordi Guardiola, Xavier Juanola, et al.. (2025). Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country. Clinical Infectious Diseases. 82(2). 282–290.
3.
4.
Notario, J., et al.. (2024). Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients. Journal of the American Academy of Dermatology. 90(5). 1059–1061. 6 indexed citations
5.
Belinchón, I., P. de la Cueva, Yolanda Gilaberte, et al.. (2023). Proyecto CUDERMA: Consenso Delphi de los indicadores de calidad para la certificación de las unidades de dermatología de atención en psoriasis. Actas Dermo-Sifiliográficas. 114(10). 865–883. 1 indexed citations
6.
Frutos, F.J. Ortiz de, Ana M. Giménez‐Arnau, L. Puig, et al.. (2023). The DERMACLEAR study: Verification results of a natural language processing system in dermatology. SHILAP Revista de lepidopterología. 2(4). 775–785. 1 indexed citations
7.
Egeberg, Alexander, et al.. (2021). Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain. Journal of Medical Economics. 24(1). 1134–1142. 5 indexed citations
8.
Alcázar, E. del, Anna López‐Ferrer, Álvaro Martínez‐Doménech, et al.. (2021). Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 35(2). e15231–e15231. 18 indexed citations
9.
Puig, L., J.M. Carrascosa, & J. Notario. (2020). Biosimilares en el tratamiento de la psoriasis. Actualización. Actas Dermo-Sifiliográficas. 111(10). 809–814. 6 indexed citations
10.
Notario, J., Jordi Bas, Ariadna Padullés, et al.. (2019). Association between infliximab concentrations and clinical response in psoriasis: a prospective cohort study. Journal of Dermatological Treatment. 32(2). 180–187. 2 indexed citations
11.
Puig, L., J.M. Carrascosa, J. Notario, & I. Belinchón. (2019). Informes de posicionamiento terapéutico: utilidad y transparencia. Actas Dermo-Sifiliográficas. 111(1). 3–6. 4 indexed citations
12.
Deza, Gustavo, J. Notario, Marta Ferrán, et al.. (2018). Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain. Rheumatology International. 38(11). 2037–2043. 3 indexed citations
13.
Narváez, Javier, et al.. (2017). Adult-onset Still's disease with atypical cutaneous manifestations. Medicine. 96(11). e6318–e6318. 44 indexed citations
14.
Almirall, Míriam, Jesús Rodríguez, Lourdes Mateo, et al.. (2016). Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clinical Rheumatology. 36(2). 439–443. 13 indexed citations
15.
Carrascosa, J.M. & J. Notario. (2014). Supervivencia en terapia biológica. ¿Sabemos a qué nos referimos? ¿ Podemos usarla?. Actas Dermo-Sifiliográficas. 105(8). 729–733. 16 indexed citations
16.
Rubio, Laia, Cristina Alonso, Olga López Serrano, et al.. (2011). Barrier function of intact and impaired skin: percutaneous penetration of caffeine and salicylic acid. International Journal of Dermatology. 50(7). 881–889. 34 indexed citations
17.
Carretero, G., L. Puig, Luis Dehesa, et al.. (2010). Metotrexato: guía de uso en psoriasis. Actas Dermo-Sifiliográficas. 101(7). 600–613. 54 indexed citations
18.
Carretero, G., L. Puig, Luis Dehesa, et al.. (2010). Guidelines on the Use of Methotrexate in Psoriasis. Actas Dermo-Sifiliográficas. 101(7). 600–613. 34 indexed citations
19.
Alonso, Cristina, Luísa Coderch, Alfons de la Maza, et al.. (2005). Liposomes as Alternative Vehicles for Sun Filter Formulations. Drug Delivery. 12(2). 83–88. 33 indexed citations
20.
Gaafar, Ayman, et al.. (2005). Clinical and Epidemiological Study of Disease Caused by Mycobacterium kansasii in the Metropolitan Area of Bilbao, Spain. Archivos de Bronconeumología. 41(4). 189–196. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annunziata Dattola Breakdown of academic impact, for papers by Arnd Jacobi Breakdown of academic impact, for papers by Shivani B. Kaushik Breakdown of academic impact, for papers by Nicoletta Bernardini Breakdown of academic impact, for papers by Dagmar Wilsmann‐Theis Breakdown of academic impact, for papers by M. Sánchez‐Regaña Breakdown of academic impact, for papers by Darío Kivelevitch Breakdown of academic impact, for papers by Gamze Pişkin Breakdown of academic impact, for papers by A.L.A. Kuijpers Breakdown of academic impact, for papers by E. Archier
Rankless by CCL
2026